Cargando…
Glycosylated Delta-receptor-binding domain mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge
Mucosal COVID-19 vaccines are needed to block SARS-CoV-2 infection at the mucosal site. Intranasal delivery of a glycosylated Delta variant receptor-binding domain (Delta-RBD) mucosal vaccine elicited potent and balanced systemic antibody titers comparable to those induced by the intramuscular injec...
Autores principales: | Guan, Xiaoqing, Verma, Abhishek K., Wang, Gang, Shi, Juan, Perlman, Stanley, Du, Lanying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563057/ https://www.ncbi.nlm.nih.gov/pubmed/37822493 http://dx.doi.org/10.1016/j.isci.2023.108033 |
Ejemplares similares
-
mRNA vaccines elicit potent neutralization against multiple SARS-CoV-2 omicron subvariants and other variants of concern
por: Wang, Gang, et al.
Publicado: (2022) -
MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection
por: Tai, Wanbo, et al.
Publicado: (2023) -
A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection
por: Shi, Juan, et al.
Publicado: (2022) -
Delta breakthrough infections elicit potent, broad and durable neutralizing antibody responses
por: Walls, Alexandra C., et al.
Publicado: (2021) -
Broad and potent neutralizing antibodies are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection
por: Seow, Jeffrey, et al.
Publicado: (2023)